Tools
Three calculators, each doing one conversion by itself rather than asking you to trust a seller’s math: the reconstitution arithmetic, the trial dose scaled to your body weight, and what a “starting at” price actually totals. None of them recommends a dose or a seller — each computes what the numbers you enter imply, and shows the work.
Reconstitution Calculator
The single most consequential arithmetic a GLP-1 buyer does: vial strength and bacteriostatic water in, exact units to draw on a U-100 syringe out, every step shown.
Open the calculator →Trial dose vs. marketed rangeDose-by-Weight Calculator
The one adult trial used 10 mcg/kg; sellers commonly market a flat 200-300 mcg nightly. See your own trial-equivalent dose next to that range — and which one is actually higher.
Open the calculator →What 'starting at' hidesCost Calculator
Enter a monthly price, term and any up-front fee to get the true cost per month — checked against 23 real published GLP-1 prices, by format, with verification dates.
Open the calculator →Or read the boards
For questions a single conversion can’t answer — which seller, which format, whether the evidence holds up — these boards answer them with the working shown.
Every published price, lowest first
Ranked strictly on the standing month-to-month rate — never an introductory month, a first-order coupon, or a prepaid quarter divided out to look smaller. If a seller's homepage and its checkout disagreed, we used the one you would be billed on month two.
Open the board →Which format?Oral against injectable, priced separately
The comparison a calculator would get wrong. Sellers price the two formats independently, the gap runs $40 to $60 a month, and it does not run the same direction every time — one seller charges more for its oral product than for its own injection.
Open the board →Who prescribes it?Plans, not one-off checkouts
The sellers whose own pricing describes an ongoing prescribed relationship — a multi-month ladder, an auto-refill, a membership — rather than a product page that assumes you already have a script.
Open the board →Check the claimWhat the trials actually measured
−14.9% on semaglutide across 1,961 adults, −20.9% on tirzepatide across 2,539 — and the one published head-to-head between them was run in type 2 diabetes, not obesity. What that does and does not settle.
Open the board →